Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication in the class of immune checkpoint inhibitors. It selectively binds and blocks the programmed death-1 receptor on T cells, thereby facilitating their activation. From Wikipedia
Central drug inspectors flagged unauthorised oncology medicines sold at a fraction of their market price, prompting an expanded probe.
